Oryzon Genomics shares rose this Monday after learning that the European Medicines Agency (EMA) has authorized the initiation of a Phase Ib clinical trial of the molecule yadademstate for sickle cell anemia (SCA). This drug is used against highly aggressive cancers such as leukemia and works by blocking the action of a protein called LSD1, which has been shown to promote tumor cell multiplication.